Skip to main content
. 2022 Oct 28;163(5):1061–1070. doi: 10.1016/j.chest.2022.10.020

Figure 2.

Figure 2

Maximum respiratory support according to mAb treatment status among patients hospitalized within 28 days. Comparing severity of hospitalizations for 108 mAb-treated and 511 mAb-untreated patients, the maximum level of respiratory support was lower for mAb-treated patients (adjusted proportional OR, 0.25; 95% CI, 0.16-0.38). HFNC = high-flow nasal cannula; IMV = invasive mechanical ventilation; mAb, monoclonal antibody; NIV = noninvasive ventilation.